General Clinical Chemistry Analyzers and Accessories
Abcam P 22077, 10MG
MW 315.3 Da, Purity >98%. Selective USP7 (IC₅₀ = 8 μM) inhibitor. Active against closely related USP47. Selective versus SENP2c0re (IC₅₀ >50 μM) and DENI (IC₅₀ >50 μM). Destabilizes Claspin. Inhibits neuroblastoma growth by inducing p53-mediated apoptosis. Inhibits Tip60 deubiquitination.
The product is subject to the following: Abcam Restricted Use Statement
Abcam SGI1776, 10MG
MW 405.4 Da, Purity >99%. Novel ATP competitive inhibitor of Pim1 with IC50 of 7 nM, 50- and 10-fold selective versus Pim2 and Pim3. Preliminary results from studies treating prostate cancer cells.
The product is subject to the following: Abcam Restricted Use Statement
Abcam UC2288, p21 inhibitor, 10MG
MW 481.8 Da, Purity >98%. Cell-permeable, phenylcyclohexyl-urea based compound that selectively downregulates the expression of p21, independent of p53 expression, at either transcription or post-transcriptional level. Attenuates p21 protein levels with minimal effect on p21 protein stability. Has no significant effect on the activities of Raf kinases, VEGFR2 kinase, or the phosphorylation state of ERK. Effectively inhibits the growth of multiple cancer cell lines (GI₅₀ = ~ 10 μM against NCI60 cell lines).
The product is subject to the following: Abcam Restricted Use Statement
Abcam WH-4-023, 25MG
MW 568.7 Da, Purity >98%. Potent and selective inihbitor of the tyrosine kinases Lck and Src with IC₅₀ values of 2 nM for Lck and 6 nM for Src.
The product is subject to the following: Abcam Restricted Use Statement
Abcam GSK-690693 hydrochloride, ATP-competitive pan-Akt kinase inhibitor, 25MG
MW 425.5 Da, Purity >99%. Novel ATP-competitive pan-Akt kinase inhibitor (IC₅₀ values are 2, 13 and 9 nM for Akt1, 2 and 3 respectively). Also exhibits some inhibition of AMPK, PKA and PAK and PKC isoforms (IC₅₀ < 100 nM). Displays antiproliferative and apoptotic effects in tumor cell lines.
The product is subject to the following: Abcam Restricted Use Statement
Abcam LY2940680 (Taladegib), 50MG
MW 512.5 Da. Potent Hedgehog signaling pathway inhibitor. Smoothened antagonist. Inhibits growth of cancer cell lines containing a disease-relevant Smoothened gene mutation. Has anti-tumor activity in animal models.
The product is subject to the following: Abcam Restricted Use Statement
Abcam LY2940680 (Taladegib), 10MG
MW 512.5 Da. Potent Hedgehog signaling pathway inhibitor. Smoothened antagonist. Inhibits growth of cancer cell lines containing a disease-relevant Smoothened gene mutation. Has anti-tumor activity in animal models.
The product is subject to the following: Abcam Restricted Use Statement
Abcam FC 131, C x CR4 activation inhibitor, 5MG
MW 729.8 Da, Purity >95%. FC 131, CXCR4 activation inhibitor. Achieve your results faster with highly validated, pure and trusted compounds.
The product is subject to the following: Abcam Restricted Use Statement
Abcam SRT-3025 hydrochloride, 25MG
MW 606.2 Da, Purity >=98%. SRT-3025 is a potent and selective Sirt1 activator. It inhibits RANKL-induced osteoclast differentiation, fusion and resorptive capacity without affecting osteoclast survival. SRT-3025 inhibits RANKL-induced osteoclastogenesis in bone marrow-derived macrophages (BMMs) by activating AMPK and deacetylating RelA/p65 lysine 310, critical for activation of the NF-κB signaling pathway.
The product is subject to the following: Abcam Restricted Use Statement
Abcam MM-102 (HMTase Inhibitor I x ), 25MG
MW 669.8 Da, Purity >=98%. MM-102 (HMTase Inhibitor IX) is a potent WDR5/MLL interaction inhibitor (IC50 = 2.4 nM). It has been shown to block MLL1 methyltransferase activity, reducing the expression of HoxA9 and Meis-1 genes, which are both critical MLL1 target genes in MLL1 fusion protein-mediated leukemogenesis. WD-repeat protein 5 (WDR5) is a scaffold protein commonly involved in the formation of nucleosome-modifying protein complexes with histones.
The product is subject to the following: Abcam Restricted Use Statement
Abcam LGK974, 1MG
MW 396.4 Da, Purity >=98%. LGK-974 is a potent and specific inhibitor of Porcupine (porcn), a Wnt-specific acyltransferase (IC₅₀ = ~0.4 nM). GK974 potently inhibits Wnt signaling, has strong efficacy in rodent tumor models, and is well-tolerated. In addition, head and neck cancer cell lines with loss-of-function mutations in the Notch signaling pathway have a high response rate to LGK974.
The product is subject to the following: Abcam Restricted Use Statement
Abcam LRRK2-IN-1, LRRK2 inhibitor, 10MG
MW 570.7 Da. Potent and selective inhibitor of the Parkinson's disease kinase LRRK2. Benzodiazepine based derivative. Inhibits both G2019S mutant and wild-type LRRK2 kinase activity (IC₅₀ values are 6 and 13 nM respectively). Causes dephosphorylation, ubiquitination and degradation of LRRK2. Inhibits IFN-γ-induced monocyte maturation in vitro.
The product is subject to the following: Abcam Restricted Use Statement
